Researchers from Princeton University have uncovered an antibiotic molecule capable of killing both Gram-negative and Gram-positive bacteria using two simultaneous mechanisms, while also avoiding antibiotic resistance.
2020: A molecular odyssey – could artificial intelligence bring in a new age of antibiotic drug discovery?
Using machine-learning, researchers have discovered a new antibiotic that is able to kill bacteria resistant to other antibiotics.
When investigating the effect tolerance to a single drug has when combination therapy is being used to prevent antibiotic resistance, a team of researchers demonstrated that antimicrobial tolerance can promote resistance.
The US FDA has approved cefiderocol (Fetroja), a siderophore cephalosporin that inhibits bacterial cell wall synthesis. Fetroja is the first approved antibiotic that functions as a siderophore.
Researchers have developed nanomeshes as an effective drug-delivery system for antibiotics.
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Anti-Candida activity of existing antibiotics and their derivatives when used alone or in combination with antifungals’ as we ask the authors about Candida infections, the potential repurposing of antibiotics and the future of this field.
Research has suggested that prophylactic antibiotics are overprescribed before dental visits, and that taking them could actually increase the likelihood of adverse effects.
In this perspective piece for Future Microbiology the authors argue that there is a lack of innovation to meet the current shortcomings of antibiotic R&D.
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
US FDA approves RECARBRIO™ for complicated UTIs and complicated intra-abdominal infections: July’s industry headlines
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.